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a  b  s  t  r  a  c  t
Streptococcus  pyogenes  is  an important  global  pathogen,  causing  considerable  morbidity  and  mortality,
especially  in  low  and  middle  income  countries  where  rheumatic  heart  disease  and invasive  infections  are
common.  There  is  a number  of  promising  vaccine  candidates,  most  notably  those  based  on  the  M  protein,
the key  virulence  factor  for the  bacterium.  Vaccines  against  Streptococcus  pyogenes  are  considered  as
impeded  vaccines  because  of a number  of  crucial  barriers  to development.  Considerable  effort  is needed
by  key  players  to bring  current  vaccine  candidates  through  phase  III clinical  trials  and  there  is a clear
need  to develop  a roadmap  for future  development  of current  and  new  candidates.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Streptococcus pyogenes or Group A Streptococcus (GAS) causes
a massive disease burden that has been underestimated by global
health authorities. A 2005 study estimated that there are >500,000
deaths annually due to the bacteria, mostly occurring in low and
middle income countries [1].
The agent is a Gram-positive bacterium with the human as its
unique reservoir and an array of virulence factors allowing for a
very broad spectrum of clinical expression. The nasopharyngeal
mucosa and the skin, the two principal sites of asymptomatic
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colonization of GAS, represent the primary reservoirs responsi-
ble for the maintenance and transmission of GAS to a new host.
The ability of GAS to colonize and persist in skin tissue permits
transmission through person-to-person contact. GAS can also over-
come innate and acquired immune mechanisms present in saliva to
remain viable for long periods, enabling transmission from infected
persons or asymptomatic carriers via respiratory droplets [2]. In
addition, numerous outbreaks caused by food-borne GAS  have also
been reported [2].
GAS bacteria are able to penetrate normal tissue barriers lead-
ing to invasive infection at local (e.g. retropharyngeal abscess or
necrotizing fasciitis) as well as distant sites (e.g. septic arthritis). It
produces an array of superantigens that can result in streptococ-
cal toxic shock syndrome, which carries a high case fatality rate
(>50%). In addition, invasive GAS disease is a frequent cause of sep-
sis in children and adults and has a high-case fatality rate leading
to at least 150,000 deaths annually worldwide, although this ﬁgure
is almost certainly an underestimate because of sparse data from
http://dx.doi.org/10.1016/j.vaccine.2016.03.073
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many developing countries [1]. GAS can also cause invasive infec-
tion in infants (neonatal sepsis) and the mother (puerperal sepsis);
indeed, in the UK, GAS has been reported as the leading single cause
of maternal death [3].
The immune response to GAS can be disordered and early symp-
tomatic infection can lead to later, so called post-streptococcal
sequelae, including acute rheumatic fever (ARF) that in turn
leads to chronic rheumatic heart disease (RHD), as well as
post-streptococcal glomerulonephritis (PSGN). ARF/RHD is an
uncommon disease today in most resource-rich countries including
the United States, but it remains the major cause of acquired heart
disease in children, adolescents and young adults in the developing
world, responsible for at least 350,000 premature deaths per year
[4]. Available data on the prevalence of RHD suggest that there are
over 30 million people affected by RHD worldwide. PSGN is thought
to contribute to the high rates of end-stage renal failure in GAS
endemic regions [5].
GAS pharyngitis and impetigo are responsible for the greatest
absolute number of symptomatic GAS infections each year. GAS
pharyngitis affects approximately 8–15% of school-aged children
per year, whereas GAS impetigo is a very common infection in chil-
dren, especially in tropical developing countries with a prevalence
of >10%, and even over 50% in some settings [6].
GAS remains susceptible to penicillin. In spite of its widespread
use there is no evidence to suggest the burden of GAS diseases
is decreasing in low and middle-income settings. Serious chronic
disease associated with streptococcal disease has decreased in inci-
dence in high income countries in most populations. Antibiotic
treatment of pharyngitis is highly effective at preventing ARF [7],
however primary prevention programmes are resource intensive
especially for low and middle income countries [8,9]. Furthermore,
many cases (possibly over 60%) of ARF occur without a history of
symptomatic pharyngitis, and it has been hypothesized that GAS
skin infection may  also contribute to ARF [10]. For those diag-
nosed with ARF, secondary penicillin prophylaxis is effective in
preventing recurrent ARF episodes and consequent worsening of
RHD when efﬁciently delivered [11], but it requires monthly peni-
cillin injections over many years [8].
Serious GAS diseases do appear to be waning in some middle-
income countries, probably because of improved living conditions
and access to health services. However, GAS diseases continue to
exact a toll in terms of mortality, morbidity and economic costs,
even in wealthy countries, such as the important contribution of
invasive GAS disease to maternal mortality in the United Kingdom
[3].
Data are sparse on the economic burden of GAS disease, though
a recent study in Fiji found that the cost of RHD mortality over a
5 year period was over US$30 million, close to one third of one
percent of total GDP, representing a signiﬁcant economic burden
for the country [12]. An economic evaluation of interventions for
ARF/RHD found that a vaccine against GAS would be the most cost-
effective intervention for ARF/RHD in ARF-endemic regions at a cost
of between US$137–458 per DALY averted, assuming 80% efﬁcacy
and 65–95% coverage (compared with 22–33 thousand dollars for
treatment of sore throat) [13]. Even wealthy countries are affected –
a study of GAS pharyngitis in the US suggested that GAS pharyngitis
costs at least US$500 million per annum [14]. Few data are available
for impetigo, invasive disease, scarlet fever and PSGN.
Better epidemiologic data are still needed in most developing
countries, particularly on the contribution of RHD to premature
mortality and long term sequelae [15], and on the rate and mortality
of invasive disease, especially in the newborn and the new mother.
Data regarding strain diversity of the bacteria are also needed in
many low and middle income countries. Even with these limita-
tions, the current data on disease burden make a convincing case
for the need for an effective vaccine that could offer a practical
strategy for disease control and prevention, especially for ARF and
RHD.
2. Overview of current efforts
2.1. Biological feasibility for vaccine development
Although there are no currently licensed GAS vaccines, the bio-
logical feasibility for GAS vaccine development is supported by a
number of observations including the natural history of GAS infec-
tion, available serologic data from natural history studies, animal
data from pre-clinical studies, and evidence of protection from
challenge in human subjects immunized with puriﬁed M proteins.
Pre-school and school-aged children experience repeated
episodes of GAS pharyngitis and skin infection until they reach
early adulthood when these infections become far less common,
indicating that immunity to infection develops with age. One expla-
nation for this observation is that immunity is type-speciﬁc – that
is, that when a person is infected by a strain of GAS (most commonly
referred to as an M-type/emm-type) the immune response protects
them against subsequent infection due to the homologous type,
but not or less completely against heterologous types [16,17]. Over
time individuals meet multiple types of GAS and develop immu-
nity against these multiple types. An alternate or complementary
explanation is that generation of immunity requires repeated
presentation of conserved antigens before a threshold level of pro-
tective immunity is achieved. There is no direct evidence for the
latter explanation and it is not mutually exclusive with the former.
The paradigm of type-speciﬁc immunity is further supported
by elegant longitudinal studies that have observed that infection
with a single strain of GAS leads to generation of strain speciﬁc
(M-protein) antibodies that lead to a long period (up to 30 years)
of protection against the homologous strains but not against other
strains [16].
Pre-clinical (murine) studies of GAS vaccine candidates (pre-
dominantly M protein vaccines) have demonstrated protection in
challenge studies [18]. Further, subjects vaccinated with puriﬁed
M proteins from GAS were protected against challenge with vir-
ulent homologous strain of GAS [19–21]. These GAS pharyngeal
challenge studies, involving a total of 178 healthy adult volunteers
in 3 separate studies were successfully used to demonstrate efﬁcacy
of prototype M protein vaccines in the 1970s. Vaccine efﬁcacy of up
to 89% was demonstrated in these studies [19]. Importantly, GAS
challenge was  safe, with all participants responding to penicillin
therapy without complications or sequelae developing.
2.2. Serotype/strain coverage
A potential barrier to a type-speciﬁc M protein-based vaccine
is that there are >200 emm-types of GAS (the N-terminal part of
the M protein has a variable amino acid sequence resulting in anti-
genic diversity and is the basis for this widely used nucleotide based
emm-typing scheme). If type-speciﬁc antibody protection is the
major mechanism by which immunity is generated against GAS
then this clearly raises the issue of potential coverage for type-
speciﬁc vaccines. This was  highlighted in an article published in
2009 that identiﬁed that the distribution of emm-types was quite
different in developing compared to developed settings [22]. The
study observed that there was a higher diversity of strains in lower
to middle income settings versus high income settings, and indi-
cated that the theoretical coverage of a 26-valent (combination of
speciﬁc strains) vaccine would be favourable in developed sett-
ings (>72%) while strain coverage would be much lower in settings
were serious GAS disease is more common (e.g. Africa 39% and
Paciﬁc 24%). However, recent data from epidemiologic, genomic
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and in vitro studies suggest that there may  be immunologic “cross-
protection” between emm-types of GAS that may  overcome this
issue [23,24]. The hypothesis for this cross-protection is that
antibodies generated against individual emm-types may  actually
provide some protection against a selection of heterologous emm-
types. It is proposed that this cross-protection occurs within 48
emm-clusters [23]. There is ongong investigation in this area but
it does provide some hope for a broadly effective vaccine based
using a type-speciﬁc approach. There are fewer epidemiologic data
regarding coverage based on the presence or absence of conserved
antigens.
2.3. General approaches to vaccine development for this disease
for low and middle income country markets
ARF occurs predominantly in school-aged children in low and
middle-income countries because that is the age-group in which
the triggering infection (GAS pharyngitis) occurs, although in some
settings it is hypothesized that earlier skin infection may  prime the
immune system [25]. Invasive disease occurs in all ages, with an
increased incidence in infants and the elderly. PSGN occurs most
frequently in pre-school children, reﬂecting the greatest burden
of the triggering infection (GAS impetigo). Therefore, while con-
sensus in the ﬁeld has not been reached on a target age group for
vaccination, an infant or toddler schedule will likely be the most
appropriate schedule for most endemic settings, possibly with a
school entry booster dose. In non-endemic settings, a school entry
schedule that coincides with the schedule for ﬁnal TDap, IPV, and
MMR doses may  be appropriate. In areas where GAS is an impor-
tant cause of maternal and neonatal sepsis, maternal immunization
may  also be considered.
A successful vaccine could address a huge unmet public health
demand, and a vaccine that can prevent ARF (and thus RHD) as well
as invasive GAS disease has the potential to save over 500,000 pre-
mature deaths per year. In addition, prevention of GAS pharyngitis
and impetigo would have an enormous impact on reductions in
morbidity through improved quality of life as well as a major eco-
nomic impact through reduced health care expenditure on these
exceedingly common infectious disease problems of childhood.
3. Technical and regulatory assessment
Despite considerable progress, there remain a number of sig-
niﬁcant barriers to GAS vaccine development and candidates
remain in their infancy [26]. There is no clear pathway agreed by
multi-disciplinary consensus for a pathway for vaccine licensure,
although global efforts are beginning to come together through a
rudimentary roadmap for vaccine development [26,27]. GAS vac-
cines are now considered “impeded vaccines”. The major issues
include, but are not limited to: safety concerns, an incomplete
understanding of immune protection in humans, inadequate epi-
demiological data, minimal development of vaccines that contain
both type-speciﬁc emm  antigens and conserved antigens and
limited commercial interest.
A particular issue is development of a correlate of human
immune protection [28], reﬂecting the need for an improved
understanding of GAS immunity, including the immune response
to GAS skin infection, the role of T-cell immunity and the rel-
ative contributions of common conserved antigens in inducing
protective immunity. Opsonophagocytic antibodies or bactericidal
antibodies are potential correlates, but reliable and repro-
ducible assays to measure these antibodies are lacking [28].
The most frequently used functional assay is the indirect bac-
tericidal test, which is a time-consuming and methodologically
challenging test. The establishment of correlates of protection
would be much facilitated by the availability of an effective
vaccine.
Concerns regarding vaccine safety are based upon a theoretical
risk of autoimmune reactions in vaccinees leading to the devel-
opment of ARF. One small study of a crude M protein vaccine
suggested that there may  be an increased risk of ARF in vac-
cine recipients [29]; however, there are a number of concerns
about the design of this trial that make it difﬁcult to inter-
pret, and autoimmune reactions have not been observed in the
other human GAS vaccine trials involving thousands of study
subjects [18].
Better epidemiologic data are also required, for assessing burden
of disease to strengthen the case for GAS vaccine development, and
also for assessing type diversity and thus vaccine coverage more
systematically with high quality, standardized molecular typing
studies in more countries, particularly in Africa and Asia.
Combination vaccines may  be a viable approach to overcoming
“gaps” in emm type coverage achieved with multivalent vaccines
alone and to potentially broaden the immune response. However,
to date there has been minimal progress in combining antigens in
a single vaccine [30], and such a move would need to overcome
proprietary interests and intellectual property rights. It is unclear
exactly why  there has been an apparent reluctance of large phar-
maceutical companies to invest in clinical development of GAS
vaccines. The obstacles listed above, together with the percep-
tion of a questionable market for a vaccine in afﬂuent countries,
likely combine to create the impression of adverse commercial
risk.
Although the ultimate health need is for a vaccine to protect
against ARF/RHD and invasive disease, the relatively low incidence
of these diseases and the time delay between the initiating event
and disease makes these diseases potentially difﬁcult endpoints for
phase III efﬁcacy studies because trials would be complicated and
require well over 10,000 subjects [31]. However, protective efﬁ-
cacy against pharyngitis is a realistic efﬁcacy endpoint for candidate
GAS vaccines in phase III trials and prevention of GAS pharyn-
gitis should enable licensure of efﬁcacious and medically useful
vaccines. Importantly, GAS pharyngitis is well established as the
triggering event for ARF, and so prevention of pharyngitis can rea-
sonably be assumed to translate to prevention of ARF.
A potential strategy to improve understanding of GAS immunol-
ogy and also to create a pathway for relatively rapid testing of
new GAS vaccine candidates is through the development of human
GAS (pharyngeal) challenge studies. Previous studies (in the 1970s)
in over 170 volunteers have shown that this approach is feasible
[19–21], and proposals are under consideration for funding for a
revival of this approach.
4. Status of vaccine research and development activities
GAS vaccines can be broadly divided into M protein-based and
non-M protein-based vaccines. The GAS has a broad armamen-
tarium of virulence factors, but it is the M protein that is the
major virulence determinant of the organism. The M protein is a
coiled-coil protein consisting of 3 domains: an A-repeat/N-terminal
domain, which is highly variable and is used for epidemiologic
molecular typing (emm typing); a B-repeat domain (antibodies
against this region are not opsonic and some are cross-reactive
with human tissues) and a conserved C-repeat domain. The vac-
cines that have entered or are nearing clinical investigation are the
N-terminal M protein-based multivalent vaccines (26-valent and
30-valent vaccines) and conserved M protein vaccines (the J8 vac-
cine and the StreptInCor vaccine) [32–35]. There are a variety of
other vaccine candidates that are at various stages of discovery and
development (Table 1).
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Table 1
Development status of current vaccine candidates (*approaching trials).
Candidate name/Identiﬁer Stage of development Reference
Pre-clinical Phase I Phase II
M protein: 6-valent
N-terminal
X X [36]
M protein: 26-valent
N-terminal
X X X [32]
M protein: 30-valent
N-terminal
X * [33]
M protein: minimal epitope
J8
X X [34]
M protein: minimal epitope
J14/p145
X [45]
M protein: C-repeat epitope
(StreptInCor)
X * [38]
M protein: C-repeat epitopes X [46]
Three conserved antigens
(Combo)
X [43]
GAS carbohydrate X [47]
GAS carbohydrate defective
for GlcNAc side-chain
X [48]
GAS C5a peptidase X [49]
Fibronectin-binding protein X [50,51]
Streptococcal protective
antigen
X [32]
Serum opacity factor X [52]
Streptococcal pyrogenic
exotoxin A/B/C
X [53–55]
Streptococcal pili (T antigen) X [56,57]
Serine protease (SpyCEP) X [58]
Nine common antigens X [42]
Identiﬁed but untested
antigens: G-related
2-macroglobulin binding
(GRAB) protein, metal
transporter of
streptococcus (MtsA),
superoxidase dismutase,
lipoproteins
[59,60]
4.1. 26-Valent and 30-valent M protein vaccines
These vaccines consist of fused recombinant peptides from the
N-terminal region of M proteins from multiple different emm types
of GAS [32,33,36]. The original prototype multivalent vaccine was
a hexavalent vaccine that was evaluated in a phase I trial and later
expanded to a 26-valent vaccine and most recently a 30-valent vac-
cine. The 26-valent vaccine underwent a phase I/II clinical trial in
human adult volunteers and was shown to be safe and immuno-
genic [32]. Functional opsonic antibodies were induced against
all emm  types of GAS in the vaccine. The 26-valent vaccine was
reformulated into a 30-valent vaccine to increase “coverage” of cir-
culating emm types in the United States, Canada and Europe as well
as developing countries [33]. Epidemiologic surveys suggest that
the 26-valent vaccine would provide good coverage of circulating
strains of GAS in industrialized countries (over 72%) but poor cov-
erage in many developing countries (as low as 24% in the Paciﬁc
region) [22]. In preclinical studies, the 30-valent vaccine has been
shown to induce functional opsonic antibodies against all of the
emm types represented in the vaccine [24]. An intriguing ﬁnding
of the studies of the 30-valent vaccine is that antibodies produced
by the vaccine were shown to cross-opsonize a proportion of non-
vaccine emm  types of GAS [24], implying that cross-protection may
mitigate, to a greater or lesser extent, the limited coverage of the
30-valent vaccine in many tropical developing settings where GAS
disease is endemic. A phase I clinical evaluation of the 30-valent
vaccine in adult volunteers is anticipated in the third quarter of
2015.
4.2. Conserved M protein vaccines
These vaccines contain antigens from the conserved C-repeat
portion of the M protein. The StreptInCor vaccine incorporates
selected T and B-cell epitopes from the C-repeat region in a
synthetic 55 amino acid polypeptide, whereas the J8 and J14 vac-
cines contain shorter single minimal B cell epitopes from this
same region [37,38]. These vaccines have the clear advantage
of being comprised of a minimal number of antigens. Extensive
studies in mice, particularly of the J8 vaccine candidate, have
shown that these antigens produce opsonic antibodies that protect
against intraperitoneal challenge when the vaccine is administered
parenterally and against intranasal challenge when the vaccine is
administered intranasally [34,39]. The J8 vaccine has recently been
re-formulated with a CXC chemokine protease which was  able to
protect mice against both intraperitoneal challenge and also against
skin infection in a novel pyoderma mouse model [40]. Limited
epidemiological data available for the J8 peptide indicate that its
sequence is highly conserved among multiple emm  types of GAS
and across regions [41]. The J8 vaccine entered a phase 1 trial in
adult volunteers in 2013 but the results of this trial have not yet
been reported. The StreptinCor vaccine has been formulated into
GMP StreptInCor plus alum with plans to enter phase I clinical
assays in healthy adult volunteers in Brazil in 2016.
4.3. Other vaccines
Cell wall and secreted virulence factors, such as streptococcal
C5a peptidase, GAS carbohydrate and streptococcal ﬁbronectin-
binding proteins, among others, have been the subject of vaccine
research for up to 20 years with some encouraging results, par-
ticularly for C5a peptidase, but none of these candidates has
entered clinical trials [18]. More recently, a number of promis-
ing, apparently conserved, vaccine candidates have been identiﬁed
using immunization of mice with GAS gene segments [42]. In a
large study, immunization of mice with GAS gene segments and
challenge studies, identiﬁed several known and new antigens,
among them three antigens were selected for further development:
spy0416 (spyCEP), spy0167 (streptolysin O, SLO) and spy0269, a
surface exclusion protein [43]. These three antigens were combined
together in a single vaccine (so-called “Combo”) and were found
to provide broad coverage against multiple GAS strains in mouse
models [43]. Combo has not yet entered clinical trials however.
5. Likelihood for ﬁnancing
GAS vaccine development has been supported in the past by
industry (e.g. Merck support of the J8 vaccine and of the 26-valent
vaccine, ID Biomedical Corporation support of the 26-valent vac-
cine, Novartis Vaccines and Diagnostics, now GSK, support of the
Combo vaccine and Intercell, now Valneva of a similar vaccine
approach). The National Institute of Allergy and Infectious Dis-
eases (NIAID) at the US National Institutes for Health supported the
development of potential clinical trial sites in 2005–7 (Fiji, Mali,
Nicaragua, and South Africa). The Novartis Vaccines Institute for
Global Health (NVGH) included GAS vaccine development in its
2013 work programme.
In 2014 the Australian and New Zealand governments made
an initial AU$ 3 million investment into vaccine development in
these 2 countries where RHD is a public health priority through
an initiative known as CANVAS (Coalition to Advance New Vac-
cines against group A Streptococcus) [44]. The aim of CANVAS is to
evaluate potential GAS vaccine candidates for their potential to pro-
tect populations around the world with high rates of GAS diseases,
and to support the most promising candidate(s) through phase I
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and II clinical trials and, hopefully, to an efﬁcacy study against GAS
pharyngitis. The Initiative is also developing a core set of GAS strains
that a candidate vaccine should demonstrate protection against,
and an independent functional antibody assay that can be used for
all GAS vaccines in development. This will coincide with an eco-
nomic evaluation to make a case for investment in a GAS vaccine,
and work to engage industry partners and international agencies
in the hope that demonstration of feasibility and safety of a GAS
vaccine will encourage further investment to ensure a vaccine is
made available.
Moving forward it will be important to gain the interest and
support of funders with a track record in supporting vaccine devel-
opment for organisms that cause a signiﬁcant burden of disease in
low and middle income countries such as the Bill and Melinda Gates
Foundation, the Wellcome Trust, NIAID, PATH, GAVI and others.
Conﬂict of interest: ACS, JRC, JDF, NJM, EKM, FS and PRS are all
investigators or advisers to the CANVAS initiative. JBD is the lead
developer of the 30 valent M-type speciﬁc vaccine. MFG  is the lead
developer of the J8 vaccine. LG is the lead developer of the Strept-
InCor vaccine.
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